I. Conference Background and Expected Scale Organizer: It is expected to continue to be jointly hosted by authoritative institutions such as the National Clinical Research Center for Ocular Diseases, Chinese Journal of Retinal Diseases, and Shanghai Medical Quality Research Center. Time and Place: Time: June 5th - 7th, 2025 Location: Wuxi International Conference Center (No. 100, Qingshu Road, Economic Development Zone, Wuxi City, Jiangsu Province). This venue successfully hosted conferences with a scale of over ten thousand people in 2024 and has mature hardware facilities. Scale: It is expected that over 8,000 people will attend the event, gathering more than 300 top experts from home and abroad, covering clinical doctors, researchers and enterprise representatives. Ii. Prediction of Core Academic Topics Artificial intelligence and Big Data The application of AI in fundus image analysis, disease screening (such as diabetic retinopathy), and diagnosis and treatment decision-making is mainly discussed. Case sharing of AI-driven personalized treatment models may be added. 2. Frontiers of Gene and Cell Therapy Focus on the progress of clinical trials of gene therapy for hereditary retinopathy (such as Leber congenital amaurosis) and stem cell regenerative medicine. 3. Innovation in surgical techniques 3D navigation surgery, minimally invasive vitrectomy technology, and treatment plans for complex retinal detachment. 4. Systemic diseases are associated with the fundus Fundus manifestations of diabetes, hypertension, and rare diseases (such as uveitis), as well as multidisciplinary management strategies. 5. Myopia Prevention and Control and Retinal Diseases in Children Treatment of pathological myopia complications and screening techniques for retinopathy of prematurity (ROP) (such as Fuhan Medical's infant OCT wide-area imaging system). Iii. Prospects for Special Activities and Innovative Projects 1. New academic programs The full-course management collaboration network for fundus diseases: The full-course management project for fundus diseases to be launched in 2024 May announce the results of the three-year phase and promote the standardized construction of 1,000 medical centers. Young physician training: The "Star Program - Retinal Diagnosis and Treatment Skills Growth Training Camp" may expand its scale and add a surgical practical operation module. 2. Important announcements and ceremonies The "Clinical Diagnosis and Treatment Manual for Fundus Diseases in China (Revised Edition 2025)" was released and incorporated into the latest international consensus. The second phase of the "Precision Navigation 3D Teaching Video" has been launched, covering more surgical procedures. 3. Highlights of the industrial exhibition Exhibitor scale: It is expected that there will be over 125 booths (refer to 2024) showcasing AI diagnostic equipment, gene therapy reagents, etc. Also welcome to contact us, we are ZD Medical Inc. Tel : +86-187 9586 9515 Email :sales...

ZD Medical Inc.was invited to attend the first Global Ophthalmology Conference, where it joined many authoritative experts, scholars, ceos and investors in the industry to discuss the achievements of medical technology innovation and the development trends of the ophthalmology field. At this conference, many cutting-edge and highly competitive innovative technologies were showcased one after another, demonstrating the outstanding scientific research achievements and collective wisdom in the field of ophthalmology in China at present. Among them, ZD Medical Inc. won the Global Ophthalmology User Experience Award at this conference with its outstanding products and services. This is not only a high recognition of the clinical value created by ZD Medical Inc. in the field of ophthalmology diagnosis, but also highlights the leading position of ZD Medical Inc. as a pioneering force of a national brand in the field of ophthalmology imaging technology. From precise and efficient AI fundus screening to humanized remote film reading services, ZD Medical Inc.has always been committed to the mission of "safeguarding light with technology"! Standing under the spotlight of the global stage, ZD Medical Inc. will continue to join hands with its global partners, using technology as the pen and the original aspiration as the ink to write a new chapter in ophthalmic medical devices! Warm every pair of eyes with technology, stand firm in medical care, and walk with the light! ZD Medical Technology Co., Ltd. was established in 2015. Its headquarters is located in Hangzhou, China. It is a high-tech device platform specializing in the field of ophthalmic medical equipment. The company adheres to the business philosophy of "customer-centered and patient-oriented", and has always been committed to "safeguarding light with technology", striving to become a global leader in ophthalmic medical devices. Integrating R&D, production and sales, driven by technological innovation, it provides professional and high-tech ophthalmic equipment platform solutions for ophthalmologists and patients. Also welcome to contact us, we are ZD Medical Inc. Tel : +86-187 9586 9515 Email :sales@zd-med.com Whatsapp/Mobile : +86-187 9586 9515

On April 14, 2025, the installation ceremony of D500 dry eye detector developed by ZD Medical Inc.. was held in Beijing Tongren Hospital. The doctor representatives of the medical optometry Department of Yizhuang District of Tongren Hospital and the representatives of ZD Medical Inc. Company gathered together to witness this important moment. Li Shiming, director of the medical optometry Department of Yizhuang District of Tongren Hospital, and the doctors received detailed clinical application and operation training on the spot, and fully affirmed the clinical diagnostic value of this product. At the level of clinical diagnosis, D500 can accurately quantify the key indicators of dry eye with advanced technology, breaking through the ambiguity and subjectivity of previous diagnosis, greatly improving the accuracy and diagnosis rate of dry eye diagnosis, enabling clinicians to make more scientific diagnostic decisions based on accurate data, and accurately select drugs, physical therapy and other means. Effectively improve the quality of life of patients and promote the level of clinical diagnosis and treatment of dry eye to a new level. The newly upgraded dry eye detector D500 can complete a complete set of dry eye detection in only two and a half minutes, and with the automatic analysis function, it can quickly and professionally assist clinical dry eye examination, provide doctors with more accurate and efficient diagnostic support, and bring more timely and professional treatment plans for patients. The introduction of dry eye detector D500 in Yizhuang District of Tongren Hospital marks that the domestically developed equipment with two-and-a-half minute rapid dry eye detection technology has once again won the trust and recognition of the industry benchmark eye hospital. This is not only the embodiment of the strength of Zhuding medical research and development, but also the result of the company's continuous pursuit of excellence over the years. Zhiling Medical will take this installation ceremony as a new development opportunity, adhere to the mission of "protecting the light with science and technology", continue to challenge the industry's cutting-edge equipment and technology, and provide clinicians and patients with more diversified diagnosis and treatment programs, better quality and convenient diagnosis and treatment products. Also welcome to contact us, we are ZD Medical Inc. Tel : +86-187 9586 9515 Email :sales@zd-med.com Whatsapp/Mobile : +86-187 9586 9515

On the morning of December 27, 2022, the Suzhou Institute of Biomedical Engineering Technology of the Chinese Academy of Sciences and ZD medical signed a strategic cooperation agreement in Hangzhou. The two parties will focus on the ophthalmic medical device industry and devote themselves to the innovation and breakthrough of new technologies in the field of ophthalmic clinical application to benefit the general public eye disease patients. For a long time, due to the highly subdivided and highly specialized ophthalmic diseases, people's awareness and attention to ophthalmic diseases is limited, resulting in a low level of ophthalmological diagnosis and treatment in my country, and the development of domestic ophthalmic drugs and devices is also slow At a very early stage, still import-dominated. The purpose of the two parties this time is to promote the innovation and breakthrough of new technologies of China's domestic high-end ophthalmic medical devices, and realize the provision of domestic excellent and high-quality ophthalmic medical devices and system solutions for eye disease diagnosis and treatment for the majority of eye patients. In the future, ZD medical will continue to increase investment in research and development, and through this cooperation, together with the strong scientific and technological research and development strength of Suzhou Institute of Medical Engineering, Chinese Academy of Sciences, will continue to develop and innovate, comprehensively promote, and improve new technologies in the fields of fundus, dry eye and optometry. Innovation and breakthroughs provide a more complete solution for the diagnosis and treatment of eye diseases for the majority of eye patients.

Ocular Coherence Tomography (OCT)  is an exciting new technique for examining the internal structures of the eye.  The most common present applications are looking in fine detail at the retina and optic nerve although anterior segment OCTs have also been developed to examine the cornea, iris and lens. OCT uses the principle of light interference to form a cross-sectional map of the retina or optic nerve.  A super-bright light source such as a special LED is used and a beam-splitter is used to form a reference and a scanning beam.  The reference beam is reflected by a reference mirror and is re-combined with the reflected scanning beam from the eye.  A computer analyses the interference patterns which result.  By varying the position of the reference mirror, different depths of the retina can be studied.  The scanning beam is traced across the retina by a computer controlled mirror which can move the point in a horizontal, vertical or any oblique direction.  The most common strategies used for looking at the retina with this type of OCT use a series of  intersecting scans in different meridians.  This is analogous to scanning from 12 O'clock to 6 O'clock and then from 1 to 7 and so on. Following the scan, a map is built up of the  area being scanned and presented in comparison to age-matched controls. The latest OCT scanners use a newer technique known as spectral domain OCT.  This is a technique where the individual freqencies of the light are used separately to build up an image without the need for scanning the spot on the retina.  This increases the speed, accuracy and reliability of the scan. As the OCT gives an accurate cross-section of the retina, it is very useful for the diagnosis of many diseases.  Such diseases include macular holes (a full thickness hole of the retina), central serous retinopathy (the accumulation of fluid beneath the retina) and macular edema from diabetes or retinal circulation problems. One of the most important new applications of the OCT is in the monitoring of the response of the retina to Lucentis.  Lucentis is an exciting new drug used in the treatment of wet age related macular degeneration (AMD).  Tiny quantities of the drug are injected into the eye to treat this devastating disease.  The OCT has been proven to be the best way of monitoring the response and determining the need for further injections. OCT testing is widely available, including at our clinic.

On the morning of June 14, 2022, the signing ceremony of the strategic cooperation between ZD Medical and Lumenis was held at the headquarters of ZD Medical. Mr. Zhai, Senior President of Lumenis Asia Pacific, said in his speech that he is full of expectations and confidence in this cooperation. China is a major global market for Lumenis, which attracts extra attention and is also an important strategic layout direction for Lumenis in the future. This cooperation is not only the first cooperation between Lumenis and ZD medical, but also the first cooperation between a global ophthalmic medical device company and a Chinese medical device company. ZD medical not only brings sufficient confidence to Lumenis in the new field of dry eye, but also plays a key role in research and development, academics, and even the future growth of both parties. Mr. Wang, chairman of ZD medical, said that dry eye is the most common and most neglected ophthalmic disease after myopia. It is also a kind of eye health problem that most needs to be paid attention to by the public. In our country, especially in the primary medical environment, the detection and treatment of dry eye syndrome is far from universal. Therefore, we hope that through this cooperation, we can build a complete dry eye solution platform together with Lumenis. At the same time, we also uphold an open and enterprising attitude and keep moving forward. Strive to build a national ophthalmic equipment brand that can represent Chinese technology. This cooperation is the first time that a Chinese local ophthalmic device brand has cooperated with a multinational ophthalmic device manufacturer, and it has opened up a precedent for domestic ophthalmic device brands to go international. It is believed that this cooperation will not only enhance the brand influence of both parties, but also lay a good foundation for the quality management and operation capabilities of Chinese high-tech ophthalmic equipment enterprises to reach the international level. Lumenis spans the world and penetrates into the Chinese market! ZD medical grew up in China, facing  embracing the world! Both ZD medical and Lumenis are willing to work together to fight for the eye health of the people in China and the world!